B39.0

Niacin

Niacin (Vitamin B3)

An essential B vitamin that supports energy metabolism, cardiovascular health, and NAD+ production for longevity.

immunitylongevityvitamincardiovascularcholesterolNAD+
Last reviewed: February 1, 2025
9.0/10
40+ studies
Evidence
moderate
Safety
500-2000mg daily for lipid effects; 50-500mg for general health
Dose
8-24 weeks
Time to Effect
Immediate-release niacin (nicotinic acid)
Best Form

Niacin (Vitamin B3) is essential for energy metabolism and is a precursor to NAD+, a critical coenzyme for cellular energy and longevity. At higher doses, niacin has well-documented effects on improving cholesterol profiles, raising HDL and lowering LDL and triglycerides. The flush form is most effective for lipids, while niacinamide avoids flushing but doesn't affect cholesterol.

Mechanisms of Action

🔋
NAD+ Precursor

Converts to NAD+ for cellular energy

❤️
Lipid Modification

Dramatically affects cholesterol levels

🔥
Prostaglandin Release

Causes vasodilation (the 'niacin flush')

Recommended Dose

500-2000mg daily for lipid effects; 50-500mg for general health

50mg3000mg

Loading: Start with 100mg and gradually increase over weeks to minimize flush

Optimal Timing

  • With food (reduces flush)
  • Evening for lipid effects
  • Split doses for high amounts

Take with food

Best Form

Immediate-release niacin (nicotinic acid)

Alternatives: Extended-release niacin (less flush but more liver risk), Niacinamide (no flush, no lipid effects), Inositol hexanicotinate ('no-flush' - less effective)

Immediate-release is most effective for lipids. Avoid sustained-release due to liver concerns. Niacinamide doesn't affect cholesterol.

Duration

Minimum: 8 weeks

Optimal: 24 weeks

Cycling: Not required

Note: Taking with food and aspirin (30 min before) can reduce flushing. Build up dose slowly over 2-4 weeks.

Personalized Dosage Calculator

Get a dosage recommendation tailored to your body weight, age, goals, and health profile.

Set up your health profile for personalized recommendations

📈
Increased HDL

Significant increase in 'good' cholesterol

4-8 weeks
80% of users notice thispositive
📉
Lower Triglycerides

Significant reduction in triglycerides

4-8 weeks
75% of users notice thispositive
🔥
Niacin Flush

Temporary skin flushing, warmth, itching

30-60 minutes after dose
90% of users notice thistrade-off
ModerateMax safe dose: 3g/day with medical supervision
🟡
Diabetics

Monitor blood sugar; may need medication adjustment

Who Should NOT Take This

  • Active liver disease
  • Active peptic ulcer
  • Severe gout

Drug Interactions

Statinsmoderate

Combination may increase myopathy risk

Blood pressure medicationsmild

May enhance hypotensive effects

Possible Side Effects

Flushingvery common

Tip: Start low, take with food, aspirin 30 min before

Liver enzyme elevationuncommon

Tip: Monitor liver enzymes; avoid sustained-release forms

Blood sugar elevationuncommon

Tip: Monitor glucose if diabetic

Warnings

  • Flush is harmless but uncomfortable
  • Monitor liver enzymes at high doses
  • Can raise blood sugar and uric acid

Top studies from 40+ peer-reviewed papers

meta-analysisn=39195
DOI

Schandelmaier S et al. • The Cochrane database of systematic reviews (2017)

“Moderate- to high-quality evidence suggests that niacin does not reduce mortality, cardiovascular mortality, non-cardiovascular mortality, the number of fatal or non-fatal myocardial infarctions, nor the number of fatal or non-fatal strokes but is associated with side effects.”
Key Findings:
  • Participants randomised to niacin were more likely to discontinue treatment due to side effects than participants randomised to control group (RR 2.17, 95% CI 1.70 to 2.77; participants = 33,539; studies = 17; I2 = 77%; moderate-quality evidence).
  • Moderate- to high-quality evidence suggests that niacin does not reduce mortality, cardiovascular mortality, non-cardiovascular mortality, the number of fatal or non-fatal myocardial infarctions, nor the number of fatal or non-fatal strokes but is associated with side effects.
  • Benefits from niacin therapy in the prevention of cardiovascular disease events are unlikely.
meta-analysisn=145314
DOI

Xie S et al. • Atherosclerosis (2025)

“Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels.”
Key Findings:
  • Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels.
  • Further research is necessary to understand whether this effect would translate into a clinically relevant cardiovascular benefit.
  • Further research warranted to confirm findings
meta-analysis
DOI

Ferrell M et al. • Nature medicine (2024)

“The Author(s), under exclusive licence to Springer Nature America, Inc.”
Key Findings:
  • Lastly, treatment with physiological levels of 4PY, but not its structural isomer 2PY, induced expression of VCAM-1 and leukocyte adherence to vascular endothelium in mice.
  • Collectively, these results indicate that the terminal breakdown products of excess niacin, 2PY and 4PY, are both associated with residual CVD risk.
  • They also suggest an inflammation-dependent mechanism underlying the clinical association between 4PY and MACE.© 2024.
  • The Author(s), under exclusive licence to Springer Nature America, Inc.
meta-analysis
DOI

Nicola CA et al. • Nutrients (2024)

“Daily dietary intake of niacin is significantly lower in patients with glaucoma compared to the general population.”
Key Findings:
  • Daily dietary intake of niacin is significantly lower in patients with glaucoma compared to the general population.
  • Given different average daily intakes of niacin in these populations, different glaucoma definitions and several confounding variables which weaken the associations, large sample, standardised randomised controlled trials are needed to confirm the potential benefits of niacin in glaucoma.
  • Further research warranted to confirm findings
meta-analysisn=14223
DOI

Xia J et al. • Pharmacological research (2023)

“All rights reserved.”
Key Findings:
  • Low to very low certainty evidence established chromium supplements as the most effective in reducing fasting blood glucose levels and homeostasis model assessment of insulin resistance (SUCRAs: 90.4% and 78.3%, respectively).
  • Vitamin K supplements ranked best in reducing glycated hemoglobin A1c and fasting insulin levels (SUCRAs: 97.0% and 82.3%, respectively), with moderate to very low certainty evidence.
  • Vanadium supplements ranked best in lowering total cholesterol levels with very low evidence certainty (SUCRAs:100%).
  • Niacin supplements ranked best in triglyceride reductions and increasing high-density lipoprotein cholesterol levels with low to very low evidence certainty (SUCRAs:93.7% and 94.6%, respectively).
40
Total Studies
9.1/10
Avg Quality
10-154,601
Sample Size Range
2003-2025
Research Span

Study Type Distribution

Meta-Analysis
24
RCT
11
Systematic Review
3
Crossover
2

This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.